167 related articles for article (PubMed ID: 38566103)
1. The trend of dental check-up and prevalence of dental complications following the use of bone modifying agents in patients with metastatic breast and prostate cancer: analysis of data from the Korean National Health Insurance Service.
Lim AR; Park W; Moon SJ; Kim MS; Lee S
BMC Health Serv Res; 2024 Apr; 24(1):412. PubMed ID: 38566103
[TBL] [Abstract][Full Text] [Related]
2. Medication-related osteonecrosis of the jaw: knowledge and perceptions of medical professionals on the usage of bone modifying agents and dental referrals.
Acharya S; Patil V; Ravindranath V; Kudva A; Nikhil K
J Med Life; 2022 Mar; 15(3):368-373. PubMed ID: 35449990
[TBL] [Abstract][Full Text] [Related]
3. Interventions for managing medication-related osteonecrosis of the jaw.
Beth-Tasdogan NH; Mayer B; Hussein H; Zolk O
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD012432. PubMed ID: 28983908
[TBL] [Abstract][Full Text] [Related]
4. Does inflammatory dental disease affect the development of medication-related osteonecrosis of the jaw in patients using high-dose bone-modifying agents?
Ueda N; Nakashima C; Aoki K; Shimotsuji H; Nakaue K; Yoshioka H; Kurokawa S; Imai Y; Kirita T
Clin Oral Investig; 2021 May; 25(5):3087-3093. PubMed ID: 33057886
[TBL] [Abstract][Full Text] [Related]
5. Survey of Korean dentists on the awareness on bisphosphonate-related osteonecrosis of the jaws.
Yoo JY; Park YD; Kwon YD; Kim DY; Ohe JY
J Investig Clin Dent; 2010 Nov; 1(2):90-5. PubMed ID: 25427263
[TBL] [Abstract][Full Text] [Related]
6. Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study.
Hasegawa T; Hayashida S; Kondo E; Takeda Y; Miyamoto H; Kawaoka Y; Ueda N; Iwata E; Nakahara H; Kobayashi M; Soutome S; Yamada SI; Tojyo I; Kojima Y; Umeda M; Fujita S; Kurita H; Shibuya Y; Kirita T; Komori T;
Osteoporos Int; 2019 Jan; 30(1):231-239. PubMed ID: 30406309
[TBL] [Abstract][Full Text] [Related]
7. Oral risk factors associated with medication-related osteonecrosis of the jaw in patients with cancer.
Ueda N; Aoki K; Shimotsuji H; Nakashima C; Kawakami M; Imai Y; Kirita T
J Bone Miner Metab; 2021 Jul; 39(4):623-630. PubMed ID: 33420576
[TBL] [Abstract][Full Text] [Related]
8. The awareness and practice of dentists regarding medication-related osteonecrosis of the jaw and its prevention: a cross-sectional survey.
Han AL
BMC Oral Health; 2021 Mar; 21(1):155. PubMed ID: 33761923
[TBL] [Abstract][Full Text] [Related]
9. A real-world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with Denosumab.
Bracchi P; Zecca E; Brunelli C; Miceli R; Tinè G; Maniezzo M; Lo Dico S; Caputo M; Shkodra M; Caraceni AT
Cancer Med; 2023 Sep; 12(17):18317-18326. PubMed ID: 37559413
[TBL] [Abstract][Full Text] [Related]
10. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases.
Otto S; Pautke C; Van den Wyngaert T; Niepel D; Schiødt M
Cancer Treat Rev; 2018 Sep; 69():177-187. PubMed ID: 30055439
[TBL] [Abstract][Full Text] [Related]
11. [Diagnosis and treatment of medication-related osteonecrosis of the jaws from an oncologist's perspectives].
Yuan P
Zhonghua Kou Qiang Yi Xue Za Zhi; 2021 May; 56(5):415-420. PubMed ID: 33904274
[TBL] [Abstract][Full Text] [Related]
12. Medication-Related Osteonecrosis of the Jaw: A Cross-Sectional Study on the Prevalence of Cutaneous Manifestations and the Primary Care Physician's Role in its Early Diagnosis.
Whitefield S; Ilan MB; Lazarovici TS; Friedlander-Barenboim S; Kassem R; Yarom N
Am J Med; 2024 Mar; 137(3):266-272. PubMed ID: 38042241
[TBL] [Abstract][Full Text] [Related]
13. Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases.
Ikesue H; Mouri M; Tomita H; Hirabatake M; Ikemura M; Muroi N; Yamamoto S; Takenobu T; Tomii K; Kawakita M; Katoh H; Ishikawa T; Yasui H; Hashida T
Support Care Cancer; 2021 Aug; 29(8):4763-4772. PubMed ID: 33527228
[TBL] [Abstract][Full Text] [Related]
14. Antiresorptive agent-related osteonecrosis of the jaw (ARONJ) in urological malignancies: a multi-center retrospective study.
Sakai Y; Shindo T; Sato S; Takahashi A; Kunishima Y; Kato R; Itoh N; Okada M; Tachiki H; Taguchi K; Takayanagi A; Hotta H; Horita H; Matsukawa M; Matsuki M; Nishiyama K; Miyazaki A; Hashimoto K; Tanaka T; Masumori N
J Bone Miner Metab; 2021 Jul; 39(4):661-667. PubMed ID: 33704573
[TBL] [Abstract][Full Text] [Related]
15. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
Svejda B; Muschitz Ch; Gruber R; Brandtner Ch; Svejda Ch; Gasser RW; Santler G; Dimai HP
Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441
[TBL] [Abstract][Full Text] [Related]
16. The role of dental care providers in the management of patients prescribed bisphosphonates: brief clinical guidance.
Abed HH; Al-Sahafi EN
Gen Dent; 2018; 66(3):18-24. PubMed ID: 29714695
[TBL] [Abstract][Full Text] [Related]
17. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
[TBL] [Abstract][Full Text] [Related]
18. Osteoporosis therapy in patients with inflammatory rheumatic diseases and osteonecrosis of the jaw.
Schwaneck EC; Streit A; Krone M; Hartmann S; Müller-Richter U; Kübler AC; Gadeholt O; Schmalzing M; Tony HP; Brands RC
Z Rheumatol; 2020 Mar; 79(2):203-209. PubMed ID: 30796524
[TBL] [Abstract][Full Text] [Related]
19. Clinical status of established MRONJ in oncology patients continuing bone-modifying agents.
Miles E; Arya R; Sproat C; Patel V
Br Dent J; 2024 May; 236(9):683-687. PubMed ID: 38730156
[TBL] [Abstract][Full Text] [Related]
20. Preventing, identifying, and managing medication-related osteonecrosis of the jaw: a practical guide for nurses and other allied healthcare professionals.
Drudge-Coates L; Van den Wyngaert T; Schiødt M; van Muilekom HAM; Demonty G; Otto S
Support Care Cancer; 2020 Sep; 28(9):4019-4029. PubMed ID: 32307659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
